Structure of the toxic core of α-synuclein from invisible crystals

The protein α-synuclein is the main component of Lewy bodies, the neuron-associated aggregates seen in Parkinson disease and other neurodegenerative pathologies. An 11-residue segment, which we term NACore, appears to be responsible for amyloid formation and cytotoxicity of human α-synuclein. Here we describe crystals of NACore that have dimensions smaller than the wavelength of visible light and thus are invisible by optical microscopy. As the crystals are thousands of times too small for structure determination by synchrotron X-ray diffraction, we use micro-electron diffraction to determine the structure at atomic resolution. The 1.4 Å resolution structure demonstrates that this method can determine previously unknown protein structures and here yields, to our knowledge, the highest resolution achieved by any cryo-electron microscopy method to date. The structure exhibits protofibrils built of pairs of face-to-face β-sheets. X-ray fibre diffraction patterns show the similarity of NACore to toxic fibrils of full-length α-synuclein. The NACore structure, together with that of a second segment, inspires a model for most of the ordered portion of the toxic, full-length α-synuclein fibril, presenting opportunities for the design of inhibitors of α-synuclein fibrils.

[1]  Ralf Langen,et al.  Structural Organization of α-Synuclein Fibrils Studied by Site-directed Spin Labeling* , 2003, Journal of Biological Chemistry.

[2]  B. Meier,et al.  Structural and functional characterization of two alpha-synuclein strains , 2013, Nature Communications.

[3]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[4]  Janel O. Johnson,et al.  α-Synuclein Locus Triplication Causes Parkinson's Disease , 2003, Science.

[5]  Tamir Gonen,et al.  High-resolution structure determination by continuous rotation data collection in MicroED , 2014, Nature Methods.

[6]  Jun Hu,et al.  A Peptide Motif Consisting of Glycine, Alanine, and Valine Is Required for the Fibrillization and Cytotoxicity of Human α-Synuclein† , 2003 .

[7]  T. Gonen,et al.  Protein structure determination by MicroED. , 2014, Current opinion in structural biology.

[8]  Robert A. Grothe,et al.  Structure of the cross-β spine of amyloid-like fibrils , 2005, Nature.

[9]  R. Read.  Improved Fourier Coefficients for Maps Using Phases from Partial Structures with Errors , 1986 .

[10]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[11]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[12]  Susan E Daniel,et al.  Characterisation of isolated α-synuclein filaments from substantia nigra of Parkinson's disease brain , 2000, Neuroscience Letters.

[13]  P. Lansbury,et al.  The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? , 1995, Chemistry & biology.

[14]  M. Citron,et al.  Parkinson's Disease-associated α-Synuclein Is More Fibrillogenic than β- and γ-Synuclein and Cannot Cross-seed Its Homologs* , 2000, The Journal of Biological Chemistry.

[15]  P. Turner,et al.  Relativistic Hartree–Fock X‐ray and electron scattering factors , 1968 .

[16]  Andrew J. Nieuwkoop,et al.  Structured regions of α-synuclein fibrils include the early-onset Parkinson's disease mutation sites. , 2011, Journal of molecular biology.

[17]  J. Hoenicka,et al.  The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia , 2004, Annals of neurology.

[18]  S. Lindquist,et al.  α-Synuclein: membrane interactions and toxicity in Parkinson's disease. , 2010, Annual review of cell and developmental biology.

[19]  Richard Bertram,et al.  An improved hydrogen bond potential: Impact on medium resolution protein structures , 2002, Protein science : a publication of the Protein Society.

[20]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Irvine,et al.  Identification of the region of non‐Aβ component (NAC) of Alzheimer's disease amyloid responsible for its aggregation and toxicity , 2001, Journal of neurochemistry.

[22]  Heather T. McFarlane,et al.  Atomic structures of amyloid cross-β spines reveal varied steric zippers , 2007, Nature.

[23]  Koji Yonekura,et al.  Electron crystallography of ultrathin 3D protein crystals: Atomic model with charges , 2015, Proceedings of the National Academy of Sciences.

[24]  Jeannie Chen,et al.  Investigation of α-Synuclein Fibril Structure by Site-directed Spin Labeling* , 2007, Journal of Biological Chemistry.

[25]  J Q Trojanowski,et al.  A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly* , 2001, The Journal of Biological Chemistry.

[26]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[27]  Tamir Gonen,et al.  Three-dimensional electron crystallography of protein microcrystals , 2013, eLife.

[28]  Fred H. Gage,et al.  In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.

[29]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[30]  F. Gillardon,et al.  Functional protein kinase arrays reveal inhibition of p‐21‐activated kinase 4 by α‐synuclein oligomers , 2007, Journal of neurochemistry.

[31]  U Inserm,et al.  Causal relation between α synuclein gene duplication and familial Parkinson’s disease , 2005 .

[32]  Upendra K. Kar,et al.  Impairment of Mitochondria in Adult Mouse Brain Overexpressing Predominantly Full-Length, N-Terminally Acetylated Human α-Synuclein , 2013, PloS one.

[33]  Nicholas K. Sauter,et al.  New Python-based methods for data processing , 2013, Acta crystallographica. Section D, Biological crystallography.

[34]  D. Neill,et al.  Aggregates from mutant and wild‐type α‐synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β‐sheet and amyloid‐like filaments , 1998, FEBS letters.

[35]  Sébastien Boutet,et al.  Accurate macromolecular structures using minimal measurements from X-ray free-electron lasers , 2014, Nature Methods.

[36]  H. Jäckle,et al.  Pre‐fibrillar α‐synuclein variants with impaired β‐structure increase neurotoxicity in Parkinson's disease models , 2009, The EMBO journal.

[37]  Harry B. Gray,et al.  α-Synuclein structures from fluorescence energy-transfer kinetics: Implications for the role of the protein in Parkinson's disease , 2004 .

[38]  David Eisenberg,et al.  Identifying the amylome, proteins capable of forming amyloid-like fibrils , 2010, Proceedings of the National Academy of Sciences.

[39]  A. Brunger.  Version 1.2 of the Crystallography and NMR system , 2007, Nature Protocols.

[40]  H. Braak,et al.  100 years of Lewy pathology , 2013, Nature Reviews Neurology.

[41]  Ralf Langen,et al.  A combinatorial NMR and EPR approach for evaluating the structural ensemble of partially folded proteins. , 2010, Journal of the American Chemical Society.

[42]  C. Dobson,et al.  Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation , 2015, Proceedings of the National Academy of Sciences.

[43]  P. Zwart,et al.  Towards automated crystallographic structure refinement with phenix.refine , 2012, Acta crystallographica. Section D, Biological crystallography.

[44]  T. Iwatsubo,et al.  Biochemical Characterization of the Core Structure of α-Synuclein Filaments* , 2002, The Journal of Biological Chemistry.

[45]  Michael A. Geeves,et al.  Targeted Amino-Terminal Acetylation of Recombinant Proteins in E. coli , 2010, PloS one.

[46]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[47]  M. Feany,et al.  Aggregated α-Synuclein Mediates Dopaminergic Neurotoxicity In Vivo , 2007, The Journal of Neuroscience.

[48]  G. Bricogne,et al.  Refinement of severely incomplete structures with maximum likelihood in BUSTER-TNT. , 2004, Acta crystallographica. Section D, Biological crystallography.

[49]  P. Lansbury,et al.  Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. , 2003, Annual review of neuroscience.

[50]  T. Gonen,et al.  Structure of catalase determined by MicroED , 2014, eLife.

[51]  T. Creighton.  Methods in Enzymology , 1968, The Yale Journal of Biology and Medicine.

[52]  Michel Goedert,et al.  Identification of two distinct synucleins from human brain , 1994, FEBS letters.

[53]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[54]  A Dürr,et al.  Causal relation between α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.

[55]  Jason T. Stevens,et al.  Structure-based design of non-natural amino-acid inhibitors of amyloid fibril formation , 2011, Nature.

[56]  Olaf Riess,et al.  AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease , 1998, Nature Genetics.

[57]  Henning Stahlberg,et al.  The fold of α-synuclein fibrils , 2008, Proceedings of the National Academy of Sciences.

[58]  J. Whitelegge,et al.  Full Subunit Coverage Liquid Chromatography Electrospray Ionization Mass Spectrometry (LCMS+) of an Oligomeric Membrane Protein , 2002, Molecular & Cellular Proteomics.

[59]  U Weierstall,et al.  Injector for scattering measurements on fully solvated biospecies. , 2012, The Review of scientific instruments.